Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 ...Middle East

SHANGHAI and HONG KONG, June 3, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology...

Hence then, the article about antengene announces publication of abstract on xpo1 inhibitor selinexor in relapsed or refractory multiple myeloma at asco 2021 and eha 2021 was published today ( Friday 04/06/2021 - 03:32 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 )

Also on site :

• Gaza plan phase two: US to discuss Hamas disarmament, Israeli withdrawal
• ‘I hope they show humanity’: Greenlanders fear Trump’s desire for minerals
• Amazon Has 'Super Warm' and ‘Soft' Mini Sheepskin Boots on Sale for $50, and They're 'Worth Every Penny'